Concepedia

Andrew Brearley

AB

Statistics

Publications

4

Citations

328

H-Index

4

Active since

2009

Affiliations

Eli Lilly (United States)(Current)

Evotec (Germany)

Evotec (United Kingdom)

Novartis (United Kingdom)

Andrew Brearley is an author at Eli Lilly (United States) specializing in pharmacology, medicinal chemistry, and molecular pharmacology.

ORCID

Publications per year

2009–2022

4

Publications

4

Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy

Todd Bosanac, Robert Hughes, Thomas M. Engber et al. · Brain · 2021 · 149 citations · Full text

, , +13

Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules

Yun Shi, Philip S. Kerry, Jeffrey D. Nanson et al. · Molecular Cell · 2022 · 142 citations · Full text

, , +17

A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of β2-adrenoceptor agonists as inhaled long-acting bronchodilators

David T. Beattie, Michelle Bradley, Andrew Brearley et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 27 citations · Full text

, , +16

Synthesis and evaluation of two series of 4′-aza-carbocyclic nucleosides as adenosine A2A receptor agonists

David T. Beattie, Andrew Brearley, Zarin Brown et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 10 citations · Full text

, , +11

1–4 of 4